Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.
Anti-regulatory T cells
Arginase
IO112
Immune-modulating vaccines
PIVAC 18
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
29
05
2019
accepted:
24
10
2019
pubmed:
7
11
2019
medline:
28
11
2019
entrez:
7
11
2019
Statut:
ppublish
Résumé
L-arginine depletion by regulatory cells and cancer cells expressing arginase-1 (Arg-1) is a vital contributor to the immunosuppressive tumor microenvironment in patients with cancer. We have recently described the existence of pro-inflammatory effector T cells that recognize Arg-1. Hence, Arg-1-specific self-reactive T cells are a naturally occurring part of the memory T-cell repertoire of the human immune system. Here, we further characterize a highly immunogenic epitope from Arg-1. We describe frequent T-cell-based immune responses against this epitope in patients with cancer, as well as in healthy donors. Furthermore, we show that Arg-1-specific T cells expand in response to the T
Identifiants
pubmed: 31690955
doi: 10.1007/s00262-019-02425-6
pii: 10.1007/s00262-019-02425-6
doi:
Substances chimiques
Cancer Vaccines
0
Epitopes, T-Lymphocyte
0
Arginase
EC 3.5.3.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM